β¨ Medicine Consent Notices
30 AUGUST
NEW ZEALAND GAZETTE
2811
Product:
Active Ingredient(s):
Dosage Form:
New Zealand Sponsor:
Manufacturer(s):
Dilatrend
Carvedilol 25mg
Tablet
Roche Products (New Zealand) Limited
Roche Diagnostics GmbH, Mannheim, Germany
Product:
Active Ingredient(s):
Dosage Form:
New Zealand Sponsor:
Manufacturer(s):
Dilatrend
Carvedilol 3.12mg
Tablet
Roche Products (New Zealand) Limited
Roche Diagnostics GmbH, Mannheim, Germany
Product:
Active Ingredient(s):
Dosage Form:
New Zealand Sponsor:
Manufacturer(s):
Dilatrend
Carvedilol 6.25mg
Tablet
Roche Products (New Zealand) Limited
Roche Diagnostics GmbH, Mannheim, Germany
Product:
Active Ingredient(s):
Dosage Form:
New Zealand Sponsor:
Manufacturer(s):
Femara
Letrozole 2.5mg
Film coated tablet
Novartis New Zealand Limited
Novartis Pharma Stein AG/SA, Stein, Switzerland
Product:
Active Ingredient(s):
Dosage Form:
New Zealand Sponsor:
Manufacturer(s):
Zoloft
Sertraline hydrochloride 111.9mg equivalent to 100 mg sertraline
Film coated tablet
Pfizer Laboratories Limited
Pfizer Italiana SpA, Borgo San Michele, Latina, Italy
Pfizer Limited, Sandwich, Kent, England
Pfizer Pty Limited, West Ryde, New South Wales, Australia
Product:
Active Ingredient(s):
Dosage Form:
New Zealand Sponsor:
Manufacturer(s):
Zoloft
Sertraline hydrochloride 223.8mg equivalent to 200 mg sertraline
Film coated tablet
Pfizer Laboratories Limited
Pfizer Limited, Sandwich, Kent, England
Pfizer Pty Limited, West Ryde, New South Wales, Australia
Product:
Active Ingredient(s):
Dosage Form:
New Zealand Sponsor:
Manufacturer(s):
Zoloft
Sertraline hydrochloride 56mg equivalent to 50mg Sertraline
Film coated tablet
Pfizer Laboratories Limited
Pfizer Italiana SpA, Borgo San Michele, Latina, Italy
Pfizer Limited, Sandwich, Kent, England
Pfizer Pty Limited, West Ryde, New South Wales, Australia
Dated this 22nd day of August 2001.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go6052
Renewal of Provisional Consent to the Distribution of New Medicines
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product:
Active Ingredient(s):
Dosage Form:
New Zealand Sponsor:
Manufacturer(s):
Actigall
Ursodeoxycholic acid 300mg
Capsule
Novartis New Zealand Limited
Novartis Pharmaceuticals Corporation, Suffern, New York, United States of America
Note: This consent is valid for 2 years from 7 September 2001.
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2001, No 109
Gazette.govt.nz —
NZ Gazette 2001, No 109
β¨ LLM interpretation of page content
π₯
Consent to the Distribution of Changed Medicines
(continued from previous page)
π₯ Health & Social Welfare22 August 2001
Medicines Act 1981, Dilatrend, Femara, Zoloft, Roche Products (New Zealand) Limited, Novartis New Zealand Limited, Pfizer Laboratories Limited
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Renewal of Provisional Consent to the Distribution of New Medicines
π₯ Health & Social WelfareMedicines Act 1981, Actigall, Novartis New Zealand Limited